A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF

Cancer Investigation

Volumn 23, Issue 4, 2005, Pages 303-308

  Lewis, Karl D ^a   Gibbs, Peter ^b   O'Day, Steven ^c   Richards, Jon ^d   Weber, Jeffrey ^e   Anderson, Clay ^f   Zeng, Chan ^a   Baron, Anna ^a   Russ, Paul ^a   Gonzalez, Rene ^a,g  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c Cancer Institute Medical Group   (United States)

^d ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF MISSOURI   (United States)

^g Cutaneous Oncology Program   (United States)

Author keywords

Biochemotherapy; Brain metastases; IL 2; Melanoma; Temozolomide

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CISPLATIN; DIPHENOXYLATE; DOPAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LOPERAMIDE; PARACETAMOL; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; EDEMA; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; VOMITING; BRAIN TUMOR; EYE TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; REPRODUCIBILITY; SKIN TUMOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DACARBAZINE; EYE NEOPLASMS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 24744458382     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1081/CNV-58832     Document Type: Article

References (15)

1. Buzaid, A.C. Biochemotherapy for advanced melanoma. Crit. Rev. Oncol./Hematol. 2002, 44, 103-108.
2. Gibbs, P.; Iannucci, A.; Becker, M.; Allen, J.; O'Driscoll, M.; McDowell, K.; Williams, P.; Rosse, P.; Murphy, J.; Gonzalez, R. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma. Melanoma Res. 2000, 10, 171-179.
3. McDermott, D.F.; Mier, J.W.; Lawrence, D.P.; van der Brink, M.R.M.; Clancy, M.A.; Rubin, K.M.; Atkins, M.B. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma. Clin. Cancer Res. 2000, 6, 2201-2208.
4. O'Day, S.; Gammon, G.; Boasberg, P.D.; Martin, M.M.; Kristedja, T.S.; Guo, M.; Stern, S.; Edwards, S.; Founier, P.; Weisberg, M.; Cannon, M.; Fawzy, N.W.; Johnson, T.D.; Essner, R.; Foshag, L.J.; Morton, D.L. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol. 1999, 17, 2752-2761.
5. Middleton, M.R.; Grob, J.J.; Aaronson, N.; Fierlbeck, G.; Tilgen, W.; Seiter, S.; Gore, M.; Aamdal, S.; Cebon, J.; Coates, A.; Dreno, B.; Henz, M.; Schadendorf, D.; Kapp, A.; Weiss, J.; Fraass, U.; Statkevich, P.; Muller, M.; Thatcher, N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000, 18, 158-166.
6. Biasco, G.; Pantaleo, M.A.; Casadei, S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med. 2001, 345, 621-622.
7. Paul, M.J.; Summers, Y.; Calvert, A.M.; Rustin, G.; Brampton, M.H.; Thatcher, N.; Middleton, M.R. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002, 72, 175-178.
8. Keilholz, U.; Scheibenbogen, C.; Tilgen, W.; Bergmann, L.; Weidmann, E.; Seither, E.; Richter, M.; Brado, B.; Mitrou, P.S.; Hunstein, W. Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 1993, 72, 607-614.
9. Grabstein, K.H.; Urdal, D.L.; Tushinski, R.J.; Mochizuki, D.Y.; Price, V.L.; Cantrell, M.A.; Gillis, S.; Conlon, P.J. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986, 232, 506-508.
10. Wing, E.J.; Magee, D.M.; Whiteside, T.L.; Kaplan, S.S.; Shadduck, R.K. Recombinant human granulocyte/macrophage colony-stimulatin factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood 1989, 73, 643-646.
11. Chachoua, A.; Oratz, R.; Hoogmoed, R.; Caron, D.; Peace, D.; Liebes, L.; Blum, R.H.; Vilcek, J. Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J. Immunother. Emphas. Immunol. 1994, 15, 217-224.
12. Bell, D.; Young, J.W.; Banchereau, J. Dendritic cells. Adv. Immunol. 1999, 72, 255-324.
13. Richards, J.M.; Gale, D.; Mehta, N.; Lestingi, T. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma. J. Clin. Oncol. 1999, 77, 651-657.
14. Boasberg, P.D.; O'Day, S.J.; Kristedja, T.S.; Martin, M.; Wang, H.; Deck, R.; Shinn, K.; Ames, P.; Tamar, B.; Petrovich, Z. Biochemotherapy for metastatic melanoma with limited central nervous system involvement. Oncology 2003, 64, 328-335.
15. Atkins, M.B.; Gollob, J.A.; Sosman, J.A.; McDermott, D.F.; Tutin, L.; Sorokin, P.; Parker, R.A.; Mier, J.W. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and 1FN-α2B in patients with metastatic melanoma. Clin. Cancer Res. 2002, 8, 3075-3081.